Clovis' Rociletinib Blocked By Tagrisso 'Elephant' At ODAC
This article was originally published in Scrip
Executive Summary
There was a big elephant in the room on April 12 blocking any chance Clovis Oncology Inc.'s experimental lung cancer drug rociletinib had at gaining the backing of an FDA advisory panel: AstraZeneca PLC's Tagrisso (osimertinib), which demonstrated a better response rate and safety profile in clinical testing than its potential rival and, critically important, already is approved for the US market.